Understanding the molecular subtypes of cholangiocarcinoma (CCA) is crucial for optimizing surgical decisions and patient outcomes.

• CCA shows significant heterogeneity, with distinct genomic profiles linked to tumor location—this may affect surgical approach.
• Intrahepatic CCAs frequently harbor targetable mutations like FGFR2 fusions and IDH1/2 mutations, offering new avenues for therapy.

Surgeons can enhance patient selection based on these molecular characteristics to improve treatment strategies and outcomes.

• The study highlights the need for a more precise classification system that aligns with biological characteristics, guiding surgical interventions and follow-up.

Decreased-function CYP2A6 genotypes correlate with worse outcomes for pancreatic cancer patients on S-1 therapy.

• 56.6% of patients had decreased-function genotypes, increasing lymph node metastasis (78% vs. 52.4%, p=0.001).
• Median recurrence-free survival was significantly shorter for poor metabolizers (19.2 months vs. 32.3 months, p=0.040).

Understanding genotype impact may guide treatment personalization and improve patient outcomes.

• Poor metabolizer status was linked to a 3.17 times higher risk of reduced overall survival (p=0.039).

A left-sided uncinate-first method enhances surgical precision in complex robotic pancreatoduodenectomies.

• It provides better access to the superior mesenteric artery, especially beneficial for morbidly obese patients or those with bulky tumors.
• The technique allows for earlier vascular control and reduces traction on the superior mesenteric vein.

This approach could become essential in cases where traditional methods fall short, ultimately improving patient outcomes.

• All cases achieved R0 resection with improved posterior dissection visualization.

Extrahepatic bile duct resection shows lower complications but worse survival compared to pancreaticoduodenectomy in early-stage cholangiocarcinoma.

• Major complications: 5.9% for bile duct resection vs 45.3% for pancreaticoduodenectomy (p < .01)
• Length of stay: 11 days for bile duct resection vs 25 days for pancreaticoduodenectomy (p < .01)
• 5-year overall survival: 38.9% with bile duct resection vs 60.4% with pancreaticoduodenectomy (both p < .01)

Surgeons should prioritize pancreaticoduodenectomy as the standard approach whenever possible, reserving bile duct resection for select patients who are not surgical candidates for the more extensive procedure.